IDCT (rebonuputemcel)
Symptomatic, mild to moderate lumbar degenerative disc disease (DDD) in adults
Phase 3Active
Key Facts
Indication
Symptomatic, mild to moderate lumbar degenerative disc disease (DDD) in adults
Phase
Phase 3
Status
Active
Company
About DiscGenics
DiscGenics is a clinical-stage biotech pioneering regenerative cell therapies for chronic back pain caused by degenerative disc disease. The company's core technology involves proprietary, engineered progenitor cells called Discogenic Cells, designed to address the complex environment of the degenerated disc. Its lead program, IDCT, has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation and has progressed into a Phase 3 clinical trial following positive Phase 1/2 data. As a private company, DiscGenics is positioned to potentially disrupt the large and underserved market for non-surgical, disease-modifying treatments for spinal degeneration.
View full company profile